ZM 336372 is a reversible, selective inhibitor of the protein kinase Raf-1 (IC50 = 70nM). Although ZM 336372 weakly inhibits Raf-B, it is 10 fold more potent against Raf-1 and so is considered more selective towards this kinase. ZM 336372 inhibits Raf-1 by competing with ATP to bind to the protein. Alternate studies suggest that ZM 336372 can induce apoptosis in pancreatic adenocarcinoma cell lines by inhibiting glycogen synthase kinase-3β (GSK-3β) through phosphorylation of GSK-3&beta at Ser 9. In addition, ZM 336372 can suppress the proliferation of hepatocellular carcinoma cells by inhibiting hormone secretion and up-regulating cell cycle inhibitors. Furthermore, ZM 336372 can also act as an agonist towards Raf-1, activating the MAPK pathway, which can be suppressed after activation by Raf-1 itself, using a novel feedback loop in which activation is always followed by inactivation. ZM 336372 is an inhibitor of p38 α and p38 β.
1. Hall-Jackson, C.A., et al. 1999. Chem. Biol. 6: 559-568. PMID: 10421767
2. Deming, D., et al. 2008. J. Gastrointest. Surg. 12: 852-857. PMID: 18299943
3. Deming, D., et al. 2010. J. Surg. Res. 161: 28-32. PMID: 20031160
See how others have used ZM 336372 (CAS 208260-29-1). Click on the entry to view the PubMed entry .
PMID: # 11714782 Chuang, SS. et al. 2001. J. Immunol. 167: 6210-6216.
PMID: # 26649302 Biomed Res Int. 414250.